Navigation Links
World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
Date:11/13/2008

Driven by the human genome project, and research in the area of AIDS, geriatric diseases, neurosciences, and drug development (antiviral, antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents is projected to reach $32.5 billion by 2012. The shift towards proteomics from genomics in the post-genome-project research period is forecast to benefit protein related product markets in the upcoming years.

San Jose, California (PRWEB) November 13, 2008 -- Reagents used in biotechnology are complex chemical compounds used in a range of biotech related areas including biochemistry, cell biology, molecular biology, immunology, protein chemistry, pharmacology, and biotechnology research. The market is dependent to a large extent on applications of biotechnology instrumentation. With the focus shifting from the gene towards the protein, disciplines such as molecular biology and protein synthesis continue to gain wide attention from the academic and commercial sectors alike. However, highly automated instrumentation is expected to temper the use of reagents. The whole spectrum of biotech, medical, and biological technologies has facilitated researchers to develop highly specialized human biological products with significant therapeutic and commercial potential. Yet, the most significant value provided by these technologies may not be limited to their end products. Greater value will be the insights provided into the disease processes.

As stated by the recent report published by Global Industry Analysts Inc, United States and Europe collectively account for a share of nearly 65% of the global biotechnology reagents market estimated in 2008. Driven by its extensive use in large-scale commercial applicati
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
(Date:11/9/2009)... BEIJING, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Yo...e or "the Company") a leading manufacturer, develo... animal nutrient products in the,People,s Republic...uct a,conference call at 10:00 a.m. Eastern Time (...009 to discuss results for the quarter ended Septe...
(Date:11/9/2009)... DIEGO, Nov. 9 NexBio, Inc. announ...l American College of Allergy, Asthma, and Immunol...led "DAS181 (Fludase®), a Sialidase, Decrease...ry Effects in Animal Models of Asthma". ,, DAS1...pectrum host-targeting drug candidate being studie...
(Date:11/9/2009)... LONDON, November 9 Following the ...S Food and Drug Administration (FDA), privately,ow...//www.davalinternational.com ) has been informed t...(R) has been awarded an Orphan-Drug,designation fo...ALS). , ALS, also known as Lou Gehrig,s d...
(Date:11/6/2009)...ONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Bio...it has re-filed the Form 52-109F1 Certification of...tive Officer and James Long, the Chief Financial O...y 12, 2009 in connection with the annual audited f...0, 2008. ,, The Company initially filed the ann...
Breaking Biology Technology:Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3
...s, CEO of ReBuilder,Medical Technologies, Inc. (Pi... ),will be featured in an exclusive interview with...th. The interview will be posted on http://www.wa...terview will cover topics including ReBuilder Medi...initiatives, competitive,edge, recent news, and mi...
...Call/ - Quest PharmaTech Inc. (TSX,Venture Exchang...ement with,a multinational technology development ...develop oncology products based on its SonoLight T... Pharma Tech Inc. ("Quest" or the,"Company") has a...000,000,will be paid within the next twelve months...
...phagenics,Limited ("Phosphagenics") (ASX: POH, AIM...lts of its Phase 1 clinical trial that showed its,...elief drug oxycodone,through the skin without caus...results support Phosphagenics, aims to be the firs...codone patch for the management of,chronic pain., ...
Other Biology Technology:WallSt.net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3
(Date:11/6/2009)...ration is now open for the Society of Intervention...gy (IO) Therapies" Webinar, which will provide the...treatment of liver tumors, kidney tumor ablation a...tion of physicians, scientists and allied health p...through pioneering advances in image-guided therap...
(Date:11/6/2009)... generally live in harmony with their arboreal hos...ut of space in their trees of choice, the ants can...earch, published in the November issue of the Ame...nts bore into live trees, and it reopens a centuri... plants. , Ants and certain species of plants an...
(Date:11/6/2009)...mber 06, 2009) The Monell Center and the Chinese ...ing International Meeting on Taste and Smell Resea... CAS, the meeting will be the first international ... Alan Leshner, Chief Executive Officer, American ...cutive Publisher of Science magazine, will open th...
Breaking Biology News(10 mins):Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Ants are friendly to some trees, but not others 2Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 1Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 2Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 3Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 4Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 5Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 6Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 7Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 8XLHealth Appoints New Vice President of Contracting and Provider Relations 50536 1XLHealth Appoints New Vice President of Contracting and Provider Relations 50536 2Siblings target of intervention program 50533 1
...Swedish amateur boxers suggests that they have hig...inal fluid in the days following a bout, indicatin... brain function, according to a report in the Sept...AMA/Archives journals. , About 20 percent of profe...ury, according to background information in the ar...
... researchers have devised a way to use a brief bur...particles from a tiny gold launch pad. The techniq... of medicine on command from a chip implanted in t... reactions that require the controlled release of ...echnique was described Sept. 10 in a presentation ...
...s found that close to half of 154 smokers who had ...p a cigarette again within 12 months of their pot...rd were smoking at the one year mark. Sixty percen...hin two months of surgery. , The study, led by res...ne and published in the December issue of Cancer E...
Other Biology News:Amateur boxing linked to brain cell injury 2Electric jolt triggers release of biomolecules, nanoparticles 2Successful lung cancer surgery not enough to break nicotine dependence in many smokers 2Successful lung cancer surgery not enough to break nicotine dependence in many smokers 3
Mouse Anti-Human Actopaxin, phospho (Ser8) Monoclonal Antibody, Unconjugated, Clone J160-366 from BD Biosciences Pharmingen
Mouse Anti-Hamartin Monoclonal Antibody, Unconjugated, Clone 1B2 from Cell Signaling Technology
Mouse Anti-Mouse Ly 6C.2(Ly 28.2) Monoclonal Antibody, Unconjugated, Clone 5075-3.6 from CEDARLANE Laboratories Limited
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Biology Products: